Prothena Biosciences Limited
26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
Previously recorded as Neotope Biosciences Limited (to 2015)
7
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 19, 2026The maintenance fee for Treatment and Delay of Outset of Synucleinopathic and Amyloidogenic Disease (US 9,034,337) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
- 2 fees due Jan 4 to 28, 2027 · next Jan 4
- 1 fee due Apr 22, 2027The maintenance fee for Humanized Antibodies That Recognize Alpha-Synuclein (US 10,450,369) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 2 fees due Jun 24 to 30, 2027 · next Jun 24
- 1 fee due Sep 12, 2027The maintenance fee for Antibodies Recognizing Tau (US 11,926,659) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Antibodies recognizing tau (US 11,958,896) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 19, 2026
- 1 term has ended since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,697,082 | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease In force · Medium confidence | In force | Medium confidence | |
| US 9,034,337 | Treatment and Delay of Outset of Synucleinopathic and Amyloidogenic Disease In force · Medium confidence | In force | Medium confidence | |
| US 8,506,959 | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease In force · High confidence | In force | High confidence | |
| US 8,268,973 | Anti-amyloid antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 8,404,815 | Chimeric, Humanized, or Human Antibody 2A4 In force · High confidence | In force | High confidence | |
| US 8,636,981 | Detection of Amyloid Deposits Using Anti-Amyloid Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 7,928,203 | Chimeric, Humanized, or Human Antibody 2A4 In force · High confidence | In force | High confidence | |
| US 9,089,529 | Antibody formulations and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 9,884,020 | Antibody formulations and methods for treating AL amyloidosis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,517,830 | Antibody formulations and methods In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 37: 26 patents in force now held by others · 30 lapsed for an unpaid fee · 9 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
15 pending · 12 abandoned · 26 no status recorded